Dietary fat reduction and breast cancer outcome: Interim efficacy results from the women's intervention nutrition study

Journal of the National Cancer Institute

Volumn 98, Issue 24, 2006, Pages 1767-1776

  Chlebowski, Rowan T ^a   Blackburn, George L ^b   Thomson, Cynthia A ^c   Nixon, Daniel W ^d   Shapiro, Alice ^e   Hoy, M Katherine ^d   Goodman, Marc T ^f   Giuliano, Armando E ^g   Karanja, Njeri ^h   McAndrew, Philomena ⁱ   Hudis, Clifford ^j   Butler, John ^k   Merkel, Douglas ^l   Kristal, Alan ^m   Caan, Bette ⁿ   Michaelson, Richard ^o   Vinciguerra, Vincent ^p   Del Prete, Salvatore ^q   Winkler, Marion ^r   Hall, Rayna ^s   Simon, Michael ^t   Winters, Barbara L ^u   Elashoff, Robert M ^v   more..

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Cancer Prevention Research Institute   (United States)

^e PARK NICOLLET INSTITUTE   (United States)

^f UNIVERSITY OF HAWAII   (United States)

^g JOHN WAYNE CANCER INSTITUTE   (United States)

^h CENTER FOR HEALTH RESEARCH   (United States)

ⁱ Tower Hematology Oncology Medical Group   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k Kellogg Cancer Care Center   (United States)

^l EVANSTON HOSPITAL   (United States)

^m USA   (United States)

ⁿ DIVISION OF RESEARCH   (United States)

^o SAINT BARNABAS MEDICAL CENTER   (United States)

^p NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^q Bennett Cancer Center   (United States)

^r RHODE ISLAND HOSPITAL   (United States)

^s MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^t WAYNE STATE UNIVERSITY   (United States)

^u Campbell Soup Supply Company   (United States)

^v UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; EARLY CANCER; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIFESTYLE; LOG RANK TEST; LOW FAT DIET; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; NUTRIENT SUPPLY; NUTRITIONAL ASSESSMENT; NUTRITIONAL VALUE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STUDENT T TEST;

ADULT; AGED; BODY WEIGHT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DIETARY FATS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 33845894946     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj494     Document Type: Article

References (52)

1. Wynder EL, Cohen LA, Muscat JE, Winters B, Dwyer JT, Blackburn G. Breast cancer: Weighing the evidence for a promoting role of dietary fat. J Natl Cancer Inst 1997;89:766-75.
2. Prentice RL. Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research. Breast Cancer Res 2000;2:268-76.
3. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Hennekens CH, Speizer FE. Dietary fat and the risk of breast cancer. N Engl J Med 1987;316: 22-8.
4. Bingham SA, Luben R, Welch A, Wareham N, Khaw KT, Day N. Are imprecise methods obscuring a relation between fat and breast cancer? Lancet 2003;362:212-4.
5. Boyd NF, Stone J, Vogt KN, Connelly BS, Martin LJ, Minkin S. Dietary fat and breast cancer risk revisited: A meta-analysis of the published literature. Br J Cancer 2003;89:1672-85.
6. Holmes MD, Stampfer MJ, Colditz GA, Rosner B, Hunter DJ, Willett WC. Dietary factors and the survival of women with breast carcinoma [erratum in Cancer 1999;86:2707-8]. Cancer 1999;86:826-35.
7. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Trudeau ME, Hood N. Diet and breast cancer: Evidence that extremes in diet are associated with poor survival. J Clin Oncol 2003;21:2500-7.
8. Jain M, Miller AB, To T. Premorbid diet and the prognosis of women with breast cancer. J Natl Cancer Inst 1994;86:1390-7.
9. Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health Study. Cancer 1995;76:275-83.
10. Saxe GA, Rock CL, Wicha MS, Schottenfeld D. Diet and risk for breast cancer recurrence and survival. Breast Cancer Res Treat 1999;53: 241-53.
11. Prentice RL. Methodologic challenges in chronic disease population research. Biostatistics 2001;2:365-81.
12. Freedman LS, Potischman N, Kipnis V, Midthune D, Schatzkin A, Thompson FE, et al. A comparison of two dietary instruments for evaluating the fat-breast cancer relationship. Int J Epidemol 2006;35:1011-21.
13. Chlebowski RT, Rose D, Buzzard IM, Blackburn GL, Insull W Jr, Grosvenor M, et al. Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management. The Women's Intervention Nutrition Study (WINS). Breast Cancer Res Treat 1992;20:73-84.
14. Chlebowski RT, Blackburn GL, Buzzard IM, Rose DP, Martino S, Khaddekar JD, et al. Adherence to a dietary fat intake reduction program in postmenopausal women receiving therapy for early breast cancer. The Women's Intervention Nutrition Study. J Clin Oncol 1993;11:2072-80.
15. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, et al. Tamoxifen and chemotherapy for axilary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-42.
16. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 1989;12: 123-8.
17. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
18. Winters BL, Mitchell DC, Smiciklas-Wright H, Grosvenor MB, Liu W, Blackburn GL. Dietary patterns in women treated for breast cancer who successfully reduce fat intake: The Women's Intervention Nutrition Study (WINS). J Am Diet Assoc 2004;104:551-9.
19. Lohman TG, Roche AF, Martorell F, editors. Anthropometric standardization reference manual. Champaign (IL): Human Kinetics Publishers, Inc; 1988.
20. Copeland T, Grosvenor M, Mitchell DC, Smiciklas-Wright H, Marsobian V, Blackburn G, et al. Designing a quality assurance system for dietary data in a multicenter clinical trial: Women's Intervention Nutrition Study. J Am Diet Assoc 2000;100:1186-90.
21. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial. Lancet 2002;359:2131-9.
22. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802.
23. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassen J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
24. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al.; The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
25. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
26. Chlebowski RT, Blackburn GL, Elashoff RE, Thomson C, Goodman MT, Shapiro A, et al. Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women's Intervention Nutrition Study (WINS). Proc Am Soc Clin Oncol 2005;24:ABstract 10.
27. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
28. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990;8:1005-18.
29. Lin D, Wei L, Ying, Z. Checking the Cox model with cumulative sums of martingale residuals. Biometrika 1993;80:557-72.
30. Haybitle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971;44:793-7.
31. Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller LH, Ockene JK, et al. Low-fat dietary pattern and risk of invasive breast cancer. The Women's Health Initiative randomized controlled dietary modification trial. JAMA 2006;295:629-42.
32. Fung TT, Hu FB, Holmes MD, Rosner BA, Hunter DJ, Colditz GA, et al. Dietary patterns and the risk of postmenopausal breast cancer. Int J Cancer 2005;116:116-21.
33. Salmon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-92.
34. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
35. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N Engl J Med 2005;353:1659-72.
36. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-67.
37. Rose DP, Connolly JM, Chlebowski RT, Buzzard IM, Wynder EL. The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients. Breast Cancer Res Treat 1993;27:253-62.
38. Wu AH, Pike MC, Stram DO. Meta-analysis: Dietary fat intake, serum estrogen levels, and the risk of breast cancer. J Natl Cancer Inst 1999;91: 529-34.
39. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Hartwick W, et al. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 2002;20:42-51.
40. Borugian MJ, Sheps SB, Kim-Sing C, Van Patten C, Potter JD, Dunn B, et al. Insulin, macronutrient intake, and physical activity: Are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol Biomarkers Prev 2004;13:1163-72.
41. Pollack MN, Chapman JW, Shepherd L, et al. Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. Proc Am Soc Clin Oncol 2006;24:524.
42. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanovia A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-32.
43. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet 2005;6:103-11.
44. Barnard RJ, Gonzalez JH, Liva ME, Ngo TH. Effects of a low-fat, high-fiber diet and exercise program on breast cancer risk factors in vivo and tumor cell growth and apoptosis in vitro. Nutr Cancer 2006;55:28-34.
45. Clifton PM, Keogh JB, Foster PR, Noakes M. Effect of weight loss on infl ammatory and endothelial markers and FMD using two low-fat diets. Int J Obes (Lond) 2005;29:1445-51.
46. Piccart-Gebhart M. New stars in the sky of treatment for early breast cancer. N Engl J Med 2004;350:1140-2.
47. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, et al. Five year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-73.
48. Hunter D. Biochemical indicators of dietary intake. In: Willett W, editor. Nutritional epidemiology. New York: Oxford University Press; 1998. p. 174-243.
49. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002;20:1128-43.
50. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Body mass and mortality after breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2005;14:2009-14.
51. Boyd NF, Greenberg C, Lockwood G, Little L, Martin L, Byng J, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: Results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 1997;89: 488-96.
52. Pierce JP, Faerber S, Wright FA, Rock CL, Newman V, Flatt SW, et al. for the Women's Healthy Eating and Living (WHEL) Study Group. A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: The Women's Healthy Eating and Living (WHEL) Study. Control Clin Trials 2002;23: 728-56.